The clinical results of patients with acute myocardial infarction (AMI) at the left main trunk (LMT) remain unclear, especially in cases requiring percutaneous cardiopulmonary support (PCPS). Twenty seven cases of AMI at the LMT requiring emergent PCPS were retrospectively investigated. These 27 patients were aged 44–83 years (65.6 ± 8.6 years) and 20 (81.5%) were men. Peak creatine kinase (CK) leakage ranged from 538 to 34,010 IU/l (13,553 ± 7656 IU/l). Eight (29.6%) patients were discharged without mechanical support. Ten (37.0%) patients underwent left ventricular assist device (LVAD) implantation, five of whom with preoperative organ failure could not survive more than 6 months after implantation. The other nine (33.3%) patients died of low output syndrome or brain damage. The overall survival rates were 53.7, 41.3, 33.0, and 28.3% at 3 months, 6 months, 1 year, and 2 years, respectively. Multivariate analysis showed that Killip class 3/4 at hospital arrival was an independent risk factor for hospital mortality (odds ratio 20.4). Patients with more than 5 days of PCPS support period (n = 6), ≥ 4 h to revascularization (n = 6) or maximum CK leakage ≥20,000 IU/dl (n = 3) were not associated with successful PCPS or IABP weaning. The long-term clinical outcomes of patients with LMT disease requiring PCPS is devastating. Rapid cardiopulmonary resuscitation and coronary revascularization and timely insertion of LVAD before the onset of complications might lead to better survival.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Shiraishi J, Kohno Y, Sawada T, Kimura M, Ariyoshi M, Matsui A, et al. Predictors of in-hospital prognosis after primary percutaneous coronary intervention for acute myocardial infarction requiring mechanical support devices. Circ J. 2010;74:1152–7.
Hashimoto S, Shiraishi J, Nakamura T, Nishikawa M, Yanagiuchi T, Ito D, et al. Survivors of acute myocardial infarction at left main trunk undergoing primary percutaneous coronary intervention. Cardiovasc Interv Ther. 2016;31:89–95.
Neri R, Migliorini A, Moschi G, Valenti R, Dovellini EV, Antoniucci D. Percutaneous reperfusion of left main coronary disease complicated by acute myocardial infarction. Catheter Cardiovasc Interv. 2002;56:31–4.
Marso SP, Steg G, Plokker T, Holmes D, Park SJ, Kosuga K, et al. Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the ultima experience). Unprotected left main trunk intervention multi-center assessment. Am J Cardiol. 1999;83:1513–7.
Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Second intermacs annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29:1–10.
Yamauchi T, Masai T, Takeda K, Kainuma S, Sawa Y. Percutaneous cardiopulmonary support after acute myocardial infarction at the left main trunk. Ann Thorac Cardiovasc Surg. 2009;15:93–7.
Casassus F, Corre J, Leroux L, Chevalereau P, Fresselinat A, Seguy B, et al. The use of impella 2.5 in severe refractory cardiogenic shock complicating an acute myocardial infarction. J Interv Cardiol. 2015;28:41–50.
Grande P, Hindman NB, Saunamaki K, Prather JD, Hinohara T, Wagner GS. A comprehensive estimation of acute myocardial infarct size using enzymatic, electrocardiographic and mechanical methods. Am J Cardiol. 1987;59:1239–44.
Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace F, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med. 2001;134:451–8.
Sheiban I, Fragasso G, Lu C, Tonni S, Trevi GP, Chierchia SL. Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. Am Heart J. 2001;141:603–9.
Westaby S, Anastasiadis K, Wieselthaler GM. Cardiogenic shock in ACS. Part 2: role of mechanical circulatory support. Nat Rev Cardiol. 2012;9:195–208.
Jennings RB, Steenbergen C Jr, Reimer KA. Myocardial ischemia and reperfusion. Monogr Pathol. 1995;37:47–80.
Simon MA, Kormos RL, Murali S, Nair P, Heffernan M, Gorcsan J, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation. 2005;112:I32–6.
Yoshioka D, Sakaguchi T, Saito S, Miyagawa S, Nishi H, Yoshikawa Y, et al. Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: significance of intermacs level and renal function. Circ J. 2012;76:1631–8.
Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-rematch era: implications for patient selection. Circulation. 2007;116:497–505.
Klotz S, Vahlhaus C, Riehl C, Reitz C, Sindermann JR, Scheld HH. Pre-operative prediction of post-VAD implant mortality using easily accessible clinical parameters. J Heart Lung Transplant. 2010;29:45–52.
Dutt DP, Pinney SP. Clinical variability within the intermacs 1 profile: implications for treatment options. Curr Opin Cardiol. 2014;29:244–9.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Yamauchi, T., Masai, T., Fujii, K. et al. Long-term clinical results of acute myocardial infarction at the left main trunk requiring percutaneous cardiopulmonary support. J Artif Organs 20, 303–310 (2017). https://doi.org/10.1007/s10047-017-0972-7
- Percutaneous cardiopulmonary support (PCPS)
- Left ventricular assist device (LVAD)
- Acute myocardial infarction (AMI)
- Left main trunk (LMT)